Brief: Assembly Biosciences Nominates Development Candidate Abi-6250, An Orally Bioavailable HDV Entry Inhibitor

Assembly Biosciences

02/10/2023 14:37

Oct 2 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * ASSEMBLY BIOSCIENCES NOMINATES DEVELOPMENT CANDIDATE
ABI-6250,
AN ORALLY BIOAVAILABLE HDV ENTRY INHIBITOR
    * ASSEMBLY BIOSCIENCES INC - PROGRESSION INTO CLINICAL
STUDIES
PLANNED BY END OF 2024

Source text for Eikon:  ID:nGNX3k6bJL 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))